Subheadline
From market momentum to measurement reality: why precision body composition is becoming essential in GLP-1 clinical development.

Hero Summary
GLP-1 therapies are redefining obesity and metabolic care, but weight alone is no longer an adequate endpoint. This whitepaper explores how DXA enables deeper insight into body composition, treatment response, and clinical outcomes—bringing clarity to an increasingly complex therapeutic landscape.

What You’ll Learn

• Why weight-based endpoints are insufficient in the GLP-1 era
• How DXA provides a more precise, clinically meaningful view of treatment impact
• The implications of body composition data for trial design, regulatory strategy, and differentiation
• Operational considerations for integrating DXA into multi-site clinical trials
• Where leading sponsors are already gaining an advantage

As GLP-1 therapies evolve from weight loss solutions to comprehensive metabolic interventions, the industry must adopt measurement tools that reflect that complexity. 

Fill out the form to download the whitepaper below.